ICO terminated the license agreement to protect their legal interest in the license, not to take back Bertilimumab. They terminated the license on a Friday, Discover was scheduled to have the trustees sale on Monday morning. If the sale took place, Discover would have owned all of Immune's assets including all of Bertilimumab.
So I'm sure Ico's attorneys recommended to terminate the license so they wouldn't have to be entangled in a legal battle with Discover later. It puts them in a much better position legally. But they want to see Bert developed and they want to receive their $32 million in milestone payments. So they are very much on Immune's side, not Discover's. They will cooperate with Immune to sell Bert to a new party and transfer the license to the new owner/partner. Ico has been a shell for the past several years. They had/have no employees on salary and no cash until recently. After their trial failed 3 years ago, they ceased operations. Only recently they are beginning to ramp back up so have no ability to do anything with Bert on their own. Exterra/Armory was just approved by the Court this week to act as the investment banker for Bert so it is moving ahead.
